Atea Pharmaceuticals Q2 loss narrows as HCV trial expenses decline

Atea Pharmaceuticals

12/08/2026 22:28

Overview
US antiviral drug developer reported Q2 net loss per share narrowed from prior year
R&D and admin expenses declined, reflecting lower stock-based compensation and reduced HCV trial spend
Company's C-BEYOND Phase 3 HCV trial met primary and secondary endpoints

Outlook
Atea expects topline results from C-FORWARD Phase 3 trial in early Q1 2027
Company plans to submit NDA for BEM/RZR to US FDA in Q2 2027
Atea is advancing Phase 1 trial of AT-587 for HEV in immunocompromised patients

Result Drivers
HCV TRIAL COMPLETION - Lower R&D expenses driven by completion of patient visits in C-BEYOND Phase 3 HCV trial
LOWER STOCK COMPENSATION - Reduced R&D and admin expenses due to lower stock-based compensation

Company press release: ID:nGNX7nb7gp

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Loss Per Share
 
$0.41
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Atea Pharmaceuticals, Inc. is $8.00, about 58.4% above its August 11 closing price of $5.05

Reuters Recommended Reads
Aug 10 - Enanta Pharmaceuticals Q3 revenue misses estimates, hurt by lower royalties
Aug 12 - Arbutus Biopharma swings to Q2 loss as revenue falls; plans up to $230 mln shareholder returns
Aug 12 - TScan Therapeutics Q2 net loss narrows on lower R&D costs

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)